Rosacea by the numbers

Similar documents
Contact dermatitis by the numbers

Psoriasis by the numbers

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease.

Hair and nail disorders by the numbers

Skin infections by the numbers

Bullous diseases by the numbers

Connective tissue diseases by the numbers

Skin cancer by the numbers

Congenital abnormalities. by the numbers

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request )

See Important Reminder at the end of this policy for important regulatory and legal information.

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K

VACAVILLE DERMATOLOGY

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S

Impact of Chronic Conditions on Health-Related Quality of Life

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

COLLOIDAL SILVER. Compiled by. Campbell M Gold (2009) CMG Archives --()-- IMPORTANT

What are the functions of the integumentary system? What are some disorders of the integumentary system?

Asthma Management and the Allergist

Undergraduate Dermatology Curriculum July 2016

Calculate a Fraction of a Whole Number

Patricia C. McCormack, M.D., F.A.A.D.

Contribution of health care factors to the burden of skin disease in the United States

Dermatology Syllabus for 5th Year Med Students

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $

WR SKIN. DERMATOLOGY

Principles of Anatomy and Physiology

UNDERSTANDING ATOPIC DERMATITIS IN THE US

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer:

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES

Original Article. Abstract. Introduction

THE COST OF DIABETES IN ALBERTA

Clinic Clinic Information Suitable for Referral Not Suitable for Referral

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L

Source of effectiveness data The effectiveness evidence was derived from a review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a systematic review of published studies.

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition

The impact of pharmaceutical innovation on New Zealand cancer patients

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION

Pharmacy Prep. Qualifying Pharmacy Review

DERMOSCOPY. October 23-24, 2015 INTERMEDIATE COURSE. 11th Annual. New York. is pleased to announce:

Clinical profile of skin diseases in accident and emergency department attenders

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A

Dates to which data relate The effectiveness data were gathered from 1 July 1996 to 20 June No price year was reported.

The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A

Skin is a multilayered organ that covers and protects the body.

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes.

Developments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030

Research Award Recipient Survey

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S

LIFE INSURANCE COMPANIES TAKE LEAP OF FAITH

REVIEW MANAGEMENT. Clinical Review of Drugs to Reduce the Risk of Cancer CONTENTS

Dermatology GP Referral Guidelines

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research

ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Integumentary System

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18

The Cost of Diabetes in NEWFOUNDLAND & LABRADOR

STUDY. Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis. Data From National Psoriasis Foundation Survey Panels

THE COST OF DIABETES IN BRITISH COLUMBIA

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018

See Important Reminder at the end of this policy for important regulatory and legal information.

Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J

Information and Data Brief: Venous Leg Ulcers. Find out why a particular quality standard was created and the data behind it

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441

Research proposal. The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H.

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

Basics in Dermoscopy

15 th Annual South Beach Symposium Clinical + Aesthetic Dermatology Symposium February 9-12, 2017 Miami Beach, Florida

9.0 ANNUAL SPRING DERMATOLOGY REVIEW 2017 APR 28-29, 2017 FRI-SAT WHO SHOULD ATTEND UBC ROBSON SQUARE VANCOUVER BC. Family Physicians Dermatologists

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta

Cost-Motivated Treatment Changes in Commercial Claims:

The Economic Burden of Hypercholesterolaemia

Setting The setting was primary care. The economic study was carried out in the UK and the USA.

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18

See Important Reminder at the end of this policy for important regulatory and legal information.

Removing Barriers To Dermatologic Care Of The Uninsured

Global Influenza Vaccine Market: Industry Analysis & Outlook

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction

Measure #131 (NQF 0420): Pain Assessment and Follow-Up National Quality Strategy Domain: Community/Population Health*

UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS. Delineation of Privileges Department of Dermatology

The Cost Of Functional Dyspepsia Results From A Large US Employer Database

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.

Long Life Unlimited 1/31/18

THE INTEGUMENTARY SYSTEM. Body Membranes & Skin

Chapter 6: Healthcare Expenditures for Persons with CKD

Transcription:

AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Rosacea by the numbers Rosacea is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that: 84.5 million Americans one in four saw a physician for skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions. Skin disease cost the U.S. health care system $75 billion in medical, preventative, and prescription and non-prescription drug costs. One in three Americans were seen by dermatologists, who collaborate with other physicians throughout the health care system in caring for these patients. More than 1.6 million Americans sought medical treatment for rosacea in 2013, a similar number to those affected by psoriasis in the same year. Rosacea: Is prevalent in adults of all ages. Cost $165 million in medical treatment in 2013. Patients and their caregivers experience substantial loss of productivity, totaling $78 million. The charts that follow provide topline data on how rosacea contributes to the overall burden of skin disease. The full report includes data on prescription and non-prescription drug costs, and how age and insurance status and provider relate to the burden associated with rosacea and skin disease broadly. To purchase the report visit www.aad.org/bsd.

Prevalance NUMBER OF CARED-FOR INDIVIDUALS 30,000,000 25,000,000 20,000,000 15,000,000 10,000,000 5,000,000 0 1,613,610 NON-CANCEROUS SKIN GROWTHS* VIRAL AND FUNGAL WOUNDS AND BURNS CONTACT DERMATITIS * This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi PATIENTS BY AGE* 45.0% 40.0% 41.1% 35.0% 30.0% 35.0% 25.0% 20.0% 15.0% 20.8% 0.34% 10.0% 5.0% 0.0% 3.2% 0-17 18-44 45-64 65+ *Percentage of rosacea patients seen by a physician by age group.

Cost TOTAL MEDICAL COST* (IN MILLIONS USD) $9,000 $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $8,135 $7,015 $6,398 $6,052 $5,442 $2,000 $1,000 $0 $165 NON-CANCEROUS SKIN GROWTHS** WOUNDS AND BURNS SKIN CANCER*** ULCERS HAIR AND NAIL DISORDERS * In millions of dollars compared to most costly skin diseases * * This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi *** Represents combined data for melanoma and nonmelanoma skin cancer. COST OF SKIN DISEASE PER AFFECTED PERSON* $3,500.00 $3,000.00 $2,500.00 $2,000.00 $1,500.00 $1,000.00 $500.00 $0.00 $102.26 LYMPHOMA SKIN CANCER** ULCERS CONNECTIVE TISSUE BULLOUS *Compared with most costly skin diseases. ** Represents combined data for melanoma and nonmelanoma skin cancer.

Life Impact LOST PRODUCTIVITY (OPPORTUNITY COST)* $2,500 (IN MILLIONS USD) $2,000 $1,500 $1,000 $1,924 $1,570 $1,413 $940 $699 $500 $0 $78 NON-CANCEROUS WOUNDS SKIN GROWTHS** AND BURNS VIRAL AND FUNGAL CONTACT DERMATITIS * Time lost by patients and/or caregivers multiplied by average wages in 2013 ($192/day); In millions of dollars compared with skin diseases leading to the most loss of productivity * *This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi

This information is intended for personal/noncommercial use and may not be reproduced in any form by any means (electronic, mechanical, or other) or held in any information storage and retrieval systems without written permission from the publisher. Commercial use or distribution For information on obtaining copies of this publication or to license the content for distribution, please visit www.aad.org/bsd for details and to complete an application.